Thomson Reuters today announced that it has acquired GeneGo, a leading provider of biology and disease information, analytics, and decision support solutions for pharmaceutical research and development.
Effective immediately, GeneGo will become part of the Healthcare & Science business of Thomson Reuters. Financial terms of the transaction were not disclosed.
The acquisition enables Thomson Reuters to provide the pharmaceutical, biotechnology, and academic research communities with solutions that provide better understanding of the underlying mechanism of disease and potential therapies. GeneGo's scientific expertise and assets in biology-driven drug discovery complement the Thomson Reuters life sciences portfolio that covers drug pipeline competitive intelligence, patents, and chemistry.
"Thomson Reuters now provides comprehensive decision support solutions to help researchers striving to bring more effective medications to market," said Jon Brett-Harris, executive vice president at Thomson Reuters. "There is an increasing need for biology content, detailed disease insights, and analytics to support R&D productivity and to enable a more personalized approach to medicine."
GeneGo's capabilities include:
- MetaBase™, a comprehensive and respected knowledge base in systems biology.
- Expertise in analytics, data management, and value-added services.
- An experienced management team and a skilled scientific staff.
- A successful track record deploying decision support systems.
Increased emotional sensitivity linked to previous COVID-19 infection, new research suggests